We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ventyx Biosciences Inc (VTYX) USD0.0001

Sell:$13.36 Buy:$13.38 Change: $0.05 (0.37%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.05 (0.37%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.05 (0.37%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with significant unmet need. Its pipeline includes VTX958, VTX002, and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). Its lead product candidate, VTX958, is an oral, selective allosteric tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, Crohns disease, psoriatic arthritis and lupus. VTX958 is designed to selectively inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for the treatment of ulcerative colitis (UC). Its lead NLRP3 inhibitor product candidate, VTX2735, is designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.

Contact details

662 Encinitas Blvd., Ste. 250, Suite 250
United States
+1 (858) 9452393

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$651.39 million
Shares in issue:
50.85 million
United States
US dollar

Key personnel

  • William Sandborn
    President, Chief Medical Officer
  • Raju Mohan
    Chief Executive Officer, Founder, Director
  • John Nuss
    Chief Scientific Officer
  • Kathy Ogilvie
    Vice President - Translational Pharmacology and Research Operations
  • Christopher Krueger
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.